A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation
Jay W Mason,1 Thomas E Moon,2 Erin O’Boyle,3 Albert Dietz41Department of Medicine, University of Utah, Salt Lake City, UT, 2Tarizona eHealth Services, Inc., San Carlos, CA, 3AP Pharma, Redwood City, CA, 4Spaulding Clinical Research, West Bend, WI, USABackground: Regulatory concern about p...
Main Authors: | Mason JW, Moon TE, O’Boyle E, Dietz A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-03-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/a-randomized-placebo-controlled-four-period-crossover-definitive-qt-st-a16231 |
Similar Items
-
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron
by: Ottoboni T, et al.
Published: (2014-12-01) -
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
by: Gabrail N, et al.
Published: (2015-03-01) -
Effects of Azithromycin and Moxifloxacin Used Alone and Concomitantly With QTc Prolonging Medications on the QTc Interval
by: Johannesmeyer, Herman, et al.
Published: (2015) -
The corrected QT (QTc) prolongation in hyperthyroidism and the association of thyroid hormone with the QTc interval
by: Ye Seung Lee, et al.
Published: (2015-07-01) -
Choice of baseline in a multiple-dose thorough QT study (TQTS) – effect on analysis of moxifloxacin-induced QTc prolongation
by: B Tyl, S Azzam, E Reinbolt, et al.
Published: (2009-12-01)